J1 9lr2287

By: Senators Hough, Edwards, Klausmeier, Ready, Serafini, and Young

Introduced and read first time: February 4, 2019

Assigned to: Finance

A BILL ENTITLED

1 AN ACT concerning

2

3

Public Health - Co-Prescribing, Prescribing and Dispensing Opioid Overdose Reversal Drugs

4 FOR the purpose of requiring that certain guidelines for the co-prescribing of opioid 5 overdose reversal drugs be consistent with certain requirements; authorizing the 6 Secretary of Health to post on the Maryland Department of Health's website certain 7 guidelines and clinical guidance; authorizing a prescribing licensed health care 8 provider to co-prescribe or prescribe or a pharmacist to dispense an opioid overdose 9 reversal drug to certain individuals under certain circumstances; requiring a 10 prescribing licensed health care provider to routinely assess a patient's risk of being 11 likely to experience or witness an opioid overdose; authorizing a prescribing licensed 12 health care provider or a pharmacist to use certain information to determine a 13 patient's risk of being likely to experience or witness an opioid overdose; requiring a prescribing licensed health care provider or pharmacist to provide certain 14 15 information to certain patients on certain matters under certain circumstances; 16 prohibiting a prescribing licensed health care provider and pharmacist from taking 17 certain actions until the prescribing licensed health care provider or pharmacist 18 completes certain training; authorizing certain licensing boards to enforce this Act; 19 requiring a prescribing licensed health care provider to document in a patient's 20 medical record certain services provided; making conforming changes; altering a 21 certain definition; defining certain terms; and generally relating to co-prescribing, 22 prescribing, and dispensing opioid overdose reversal drugs.

- 23 BY repealing and reenacting, with amendments,
- 24 Article Health General
- 25 Section 13–3501 and 13–3502
- 26 Annotated Code of Maryland
- 27 (2015 Replacement Volume and 2018 Supplement)
- 28 BY adding to
- 29 Article Health General

31

(i)

(2)

1 Section 13–3503 2 Annotated Code of Maryland (2015 Replacement Volume and 2018 Supplement) 3 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, 4 That the Laws of Maryland read as follows: 5 6 Article - Health - General 7 13–3501. 8 (a) In this subtitle the following words have the meanings indicated. 9 "Co-prescribing" means, with respect to an opioid overdose reversal drug, the practice of prescribing the drug in conjunction with an opioid prescription for a patient at 10 an elevated risk of overdose. 11 12 "MONITORED PRESCRIPTION DRUG" HAS THE MEANING STATED IN § 21-2A-01 OF THIS ARTICLE. 13 14 [(c)] **(D)** "Opioid overdose reversal drug" means naloxone or [a similarly acting 15 and equally safe ANY OTHER drug that RAPIDLY REVERSES THE RESPIRATORY DEPRESSANT EFFECTS OF AN OPIOID MEDICATION AND is approved by the federal Food 16 and Drug Administration for the treatment of a known or suspected opioid overdose. 17 18 **(E)** "PHARMACIST" MEANS AN INDIVIDUAL WHO IS AUTHORIZED BY LAW TO 19 DISPENSE A MONITORED PRESCRIPTION DRUG. 20 **(F)** "Prescribing licensed health care provider" means an INDIVIDUAL WHO IS AUTHORIZED BY LAW TO PRESCRIBE A MONITORED 2122PRESCRIPTION DRUG. 23 13 - 3502.24The Secretary shall establish guidelines for the co-prescribing AND 25PRESCRIBING of opioid overdose reversal drugs that are applicable to all licensed health 26 care providers in the State who are authorized by law to prescribe a monitored prescription 27 drug[, as defined in § 21–2A–01 of this article]. 28 The guidelines established under subsection (a) of this section shall address 29 the co-prescribing of opioid overdose reversal drugs for patients who are: 30 At an elevated risk of overdose: and (1)

Receiving opioid therapy for chronic pain;

1 (ii) Receiving a prescription for benzodiazepines; or 2 (iii) Being treated for opioid use disorders. 3 (C) THE GUIDELINES ESTABLISHED UNDER SUBSECTION (A) OF THIS SECTION SHALL BE CONSISTENT WITH THE REQUIREMENTS OF THIS SUBTITLE. 4 5 THE SECRETARY MAY POST ON THE DEPARTMENT'S WEBSITE THE 6 GUIDELINES ESTABLISHED UNDER SUBSECTION (A) OF THIS SECTION OR ANY 7 RELATED CLINICAL GUIDANCE, INCLUDING GUIDANCE ON AVAILABLE OPIOID 8 OVERDOSE REVERSAL DRUG FORMULATIONS, PRESCRIBING TEMPLATES, AND STANDING ORDERS FOR THE OPIOID OVERDOSE REVERSAL DRUGS. 9 13-3503. 10 11 (A) **(1)** SUBJECT TO SUBSECTION (D) OF THIS SECTION, A PRESCRIBING LICENSED HEALTH CARE PROVIDER MAY CO-PRESCRIBE OR A PHARMACIST MAY 1213 DISPENSE WITHOUT A PRESCRIPTION FROM A LICENSED HEALTH CARE PROVIDER 14 AN OPIOID OVERDOSE REVERSAL DRUG IF THE PRESCRIBING HEALTH CARE 15 PROVIDER OR PHARMACIST DETERMINES THAT A PATIENT IS AT A HIGH RISK OF EXPERIENCING AN OPIOID OVERDOSE BECAUSE THE INDIVIDUAL IS: 16 17 **(I)** PRESCRIBED OPIOIDS FOR ACUTE OR CHRONIC PAIN; 18 (II)BEING TREATED FOR AN OPIOID USE DISORDER; OR 19 (III) PRESCRIBED AN OPIOID AND A BENZODIAZEPINE. 20 **(2)** THE **DEPARTMENT** SHALL **ENCOURAGE** A PRESCRIBING LICENSED HEALTH CARE PROVIDER OR PHARMACIST TO CO-PRESCRIBE OR 2122DISPENSE AN OPIOID OVERDOSE REVERSAL DRUG UNDER PARAGRAPH (1) OF THIS 23SUBSECTION. 24**(2)** SUBJECT TO SUBSECTION (D) OF THIS SECTION, A PRESCRIBING 25LICENSED HEALTH CARE PROVIDER MAY PRESCRIBE OR A PHARMACIST MAY 26DISPENSE WITHOUT A PRESCRIPTION FROM A LICENSED HEALTH CARE PROVIDER 27 AN OPIOID OVERDOSE REVERSAL DRUG IF THE PRESCRIBING HEALTH CARE 28 PROVIDER OR PHARMACIST DETERMINES THAT A PATIENT IS AT A HIGH RISK OF 29 WITNESSING AN OPIOID OVERDOSE BECAUSE THE INDIVIDUAL RESIDES OR SPENDS 30 TIME WITH AN INDIVIDUAL WHO:

IS PRESCRIBED AN OPIOID;

32 (II) MISUSES OPIOIDS; OR

(I)

31

L	(III)	HAS AN OPIOID USE DISORDE
L	(111)	HAS AN OPIOID USE DISORD

- 2 (B) (1) A PRESCRIBING LICENSED HEALTH CARE PROVIDER SHALL
- 3 ROUTINELY ASSESS A PATIENT'S RISK OF BEING LIKELY TO EXPERIENCE OR
- 4 WITNESS AN OPIOID OVERDOSE.
- 5 (2) A PRESCRIBING LICENSED HEALTH CARE PROVIDER OR
- 6 PHARMACIST MAY USE INFORMATION AVAILABLE TO THE PRESCRIBING LICENSED
- 7 HEALTH CARE PROVIDER OR PHARMACIST TO DETERMINE A PATIENT'S RISK OF
- 8 BEING LIKELY TO EXPERIENCE AN OPIOID OVERDOSE, INCLUDING INFORMATION
- 9 **FROM**:
- 10 (I) THE MARYLAND PRESCRIPTION DRUG MONITORING
- 11 PROGRAM;
- 12 (II) THE PATIENT'S MEDICAL RECORD; AND
- 13 (III) IF APPROPRIATE AND TO THE EXTENT ALLOWED BY LAW,
- 14 THE PATIENT'S FAMILY.
- 15 (C) IF THE PRESCRIBING LICENSED HEALTH CARE PROVIDER OR
- 16 PHARMACIST DETERMINES THAT A PATIENT IS AT RISK OF HAVING OR WITNESSING
- 17 AN OPIOID OVERDOSE, THE PRESCRIBING LICENSED HEALTH CARE PROVIDER OR
- 18 PHARMACIST SHALL:
- 19 (1) EDUCATE THE PATIENT ON THE RISKS OF AN OPIOID OVERDOSE,
- 20 INCLUDING THAT:
- 21 (I) THE MEDICATION BEING PRESCRIBED OR DISPENSED IS
- 22 ADDICTIVE AND MAY CAUSE RESPIRATORY DEPRESSION OR AN OVERDOSE WHEN
- 23 COMBINED WITH OTHER DRUGS; AND
- 24 (II) AN ANTIDOTE OR OPIOID OVERDOSE REVERSAL DRUG IS
- 25 AVAILABLE AND MAY BE PRESCRIBED OR DISPENSED WITH AN OPIOID OF 50
- 26 MORPHINE MILLIGRAM EQUIVALENTS OR HIGHER;
- 27 (2) OFFER TO PRESCRIBE OR DISPENSE AN OPIOID OVERDOSE
- 28 REVERSAL DRUG:
- 29 (3) ENCOURAGE THE PATIENT TO FOLLOW ANY DIRECTIONS FOR
- 30 USING THE DRUG BY THE FEDERAL FOOD AND DRUG ADMINISTRATION; AND

- 1 (4) STATE THAT TAKING AN OPIOID OVERDOSE REVERSAL DRUG IS 2 NOT A REPLACEMENT FOR CALLING 9-1-1 IN THE EVENT OF AN OVERDOSE.
- 3 (D) A PRESCRIBING LICENSED HEALTH CARE PROVIDER OR PHARMACIST
 4 MAY NOT PRESCRIBE OR DISPENSE AN OPIOID OVERDOSE REVERSAL DRUG UNDER
 5 THIS SECTION UNTIL THE PRESCRIBING LICENSED HEALTH CARE PROVIDER OR
 6 PHARMACIST HAS COMPLETES 1 HOUR OF TRAINING ON THE USE OF AN OPIOID
 7 OVERDOSE REVERSAL DRUG.
- 8 (E) THE APPROPRIATE LICENSING BOARD MAY ENFORCE THIS SECTION 9 AGAINST A PRESCRIBING LICENSED HEALTH CARE PROVIDER OR PHARMACIST.
- 10 **(F)** A PRESCRIBING LICENSED HEALTH CARE PROVIDER SHALL DOCUMENT 11 IN A PATIENT'S MEDICAL RECORD ANY SERVICES PROVIDED RELATED TO:
- 12 **(1)** CO-PRESCRIBING OR PRESCRIBING AN OPIOID OVERDOSE 13 REVERSAL DRUG; OR
- 14 (2) EDUCATION PROVIDED UNDER SUBSECTION (C) OF THIS SECTION.
- SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect July 16 1, 2019.